Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin d levels

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 18, Issue 3, 2013, Pages 229-233

  Liberopoulos, Evangelos N ^a   Makariou, Stefania E ^a   Moutzouri, Elisavet ^a   Kostapanos, Mixalis S ^a   Challa, Anna ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular disease; Ezetimibe; Simvastatin; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; EZETIMIBE PLUS SIMVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

25-HYDROXYVITAMIN D 2; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CALCIFEDIOL; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; GASTROINTESTINAL AGENTS; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MEMBRANE PROTEINS; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; RISK; SIMVASTATIN; UP-REGULATION; VITAMIN D DEFICIENCY;

EID: 84879234697     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412470513     Document Type: Article

References (24)

1. Makariou S, Liberopoulos EN, Elisaf M, Challa A. Novel roles of vitamin D in disease: what is new in 2011? Eur J Intern Med. 2011;22(4):355-362.
2. Nadir MA, Szwejkowski BR, Witham MD. Vitamin D and cardiovascular prevention. Cardiovasc Ther. 2010;28(4):e5-12.
3. Florentin M, Elisaf MS, Mikhailidis DP, Liberopoulos EN. Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des. 2011;16(30):3417-3434.
4. Wilczek H, Sobra J, Justova V, et al. [Iatropathogenic effect of Mevacor on vitamin D metabolism]. Cas Lek Cesk. 1989; 128(40):1254-1256.
5. Wilczek H, Sobra J, Ceska R, et al. [Monitoring plasma levels of vitamin D metabolites in simvastatin (Zocor) therapy in patients with familial hypercholesterolemia]. Cas Lek Cesk. 1994; 133(23):727-729.
6. Perez-Castrillon JL, Vega G, Abad L, et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99(7):903-905.
7. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins. Cardiovasc Drugs Ther. 2009;23(4):295-299.
8. Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D Study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D. Cardiovasc Ther. 2011;29:146-152.
9. Makariou SE, Liberopoulos EN, Agouridis AP, Challa A, Elisaf M. Effect of rosuvastatin monotherapy and in combination with fenofibrate or omega-3 fatty acids on serum vitamin D levels. J Cardiovasc Pharmacol Ther. 2012;17(4):382-386.
10. Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol. 2010;2010:957174.
11. Reboul E, Goncalves A, Comera C, et al. Vitamin D intestinal absorption is not a simple passive diffusion: evidences for involvement of cholesterol transporters. Mol Nutr Food Res. 2011; 55(5):691-702.
12. Pearson T, Ballantyne C, Sisk C, et al. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007;99(12):1706-1713.
13. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/ simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2004;26(11):1758-1773.
14. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2): 227-239.
15. Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006;69(1):56-65.
16. Guryev O, Carvalho RA, Usanov S, Gilep A, Estabrook RW. A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc Natl Acad Sci U S A. 2003;100(25): 14754-14759.
17. van Heek M, Farley C, Compton DS, et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol. 2003; 138(8):1459-1464.
18. Sertbas Y, Ersoy U, Ayter M, Gultekin Tirtil F, Kucukkaya B. Ezetimibe effect on bone mineral density and markers of bone formation and resorption. J Investig Med. 2010;58(2):295-297.
19. Kalogirou M, Tsimihodimos V, Elisaf M. Pleiotropic effects of ezetimibe: do they really exist? Eur J Pharmacol. 2010; 633(1-3):62-70.
20. Kendrick J, Targher G, Smits G, Chonchol M. 25- Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis. 2009;205(1):255-260.
21. Makariou SE, Michel P, Tzoufi MS, Challa A, Milionis HJ. Vitamin D and stroke: promise for prevention and better outcome [published online June 22, 2012]. Curr Vasc Pharmacol.
22. Makariou S, Liberopoulos E, Florentin M, et al. The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. Arch Med Sci. 2012;8(3):437-443.
23. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168(15):1629-1637.
24. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167(16):1730-1737.